Journal article
Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis
JD Brito-Sousa, HM Peixoto, A Devine, AV Silva-Neto, PCS Balieiro, VS Sampaio, S Vitor-Silva, MO Mendes, BKA Souza, MVG Lacerda, WM Monteiro
Plos Neglected Tropical Diseases | Published : 2022
Abstract
Background As quantitative glucose 6-phosphate dehydrogenase deficiency (G6PDd) screening tools are evaluated in operational studies, questions remain as to whether they are cost-effective. Here, a cost-effectiveness analysis (CEA) was performed to estimate the Incremental Cost-effectiveness Ratio (ICER) of the introduction of quantitative screening test to detect G6PDd among P. vivax carriers in two municipalities in the Brazilian Amazon. Methodology/Principal findings This cost-effectiveness analysis evaluated the use of the Standard G6PD quantitative screening test in vivax malaria treatment units in two municipalities of the Brazilian Amazon. Using the perspective of the Brazilian public..
View full abstractGrants
Awarded by Bill and Melinda Gates Foundation
Funding Acknowledgements
This study was funded by the Bill and Melinda Gates Foundation [Grant OPP1183951 to MVGL]. JDB-S is supported by the Research Support Foundation of Amazonas (FAPEAM). WMM, MVGL and VSS are fellows of the National Council for Scientific and Technological Development (CNPq). FAPEAM also funded this work through Pro '-Estado [grant 005/2019 to WMM] and POSGRAD public calls. The Oswaldo Cruz Foundation (Fiocruz) also funded this work through project n degrees 1702179682 (Produtos Inovadores/INOVA public call). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.